You just read:

Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Sep 15, 2017, 03:00 ET